Contract Services
Debiopharm, Vifor sign distribution deal in Switzerland
By
Debiopharm Group has signed a distribution and commercialization agreement with Vifor Pharma for Pamorelin LA and Salvacyl in Switzerland.
Contract Research & Services > Contract Services > News
Debiopharm Group has signed a distribution and commercialization agreement with Vifor Pharma for Pamorelin LA and Salvacyl in Switzerland.
Contract Research & Services > Contract Services > News
Furiex, Menarini sign licensing deal to commercialize Priligy
By
Furiex Pharmaceuticals and Menarini have signed a licensing deal to commercialize Priligy in Europe, Asia, Africa, Latin America and the Middle East.
Contract Research & Services > Contract Services > News CVS Caremark division unveils two medical clinics in San Antonio MinuteClinic, a division of US-based pharmacy health care provider CVS Caremark, has unveiled two new walk-in medical clinics inside CVS/pharmacy stores in San Antonio, US.
Contract Research & Services > Contract Services > News
Furiex Pharmaceuticals and Menarini have signed a licensing deal to commercialize Priligy in Europe, Asia, Africa, Latin America and the Middle East.
Contract Research & Services > Contract Services > News CVS Caremark division unveils two medical clinics in San Antonio MinuteClinic, a division of US-based pharmacy health care provider CVS Caremark, has unveiled two new walk-in medical clinics inside CVS/pharmacy stores in San Antonio, US.
Contract Research & Services > Contract Services > News
Latest Contract Services News and Insight
View all Contract Services news or find news targeted to your interests
Turkey Healthcare Infrastructure Investment & Finance Summit
Contract Research & Services > Contract Services > Events
Contract Research & Services > Contract Services > Events
Debiopharm, Vifor sign distribution deal in Switzerland
Debiopharm Group has signed a distribution and commercialization agreement with Vifor Pharma for Pamorelin LA and Salvacyl in Switzerland.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Furiex, Menarini sign licensing deal to commercialize Priligy
Furiex Pharmaceuticals and Menarini have signed a licensing deal to commercialize Priligy in Europe, Asia, Africa, Latin America and the Middle East.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
CVS Caremark division unveils two medical clinics in San Antonio
MinuteClinic, a division of US-based pharmacy health care provider CVS Caremark, has unveiled two new walk-in medical clinics inside CVS/pharmacy stores in San Antonio, US.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Arena extends lorcaserin marketing alliance with Eisai
Arena Pharmaceuticals and Eisai have extended the marketing and supply agreement for lorcaserin, an investigational drug for weight management.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
GTG signs settlement, licensing agreement with GeneSeek
Genetic Technologies (GTG) has signed a settlement and license agreement with GeneSeek of Lincoln, Nebraska, USA.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Pozen signs licensing deal with Desitin for MT 400 migraine therapy
Pozen has signed a licensing deal with Desitin Arzneimittel to develop and market MT 400 migraine therapy in 27 countries of the European Union, including Switzerland and Norway.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Monsanto enters into licensing contract with Marina
Monsanto Company has signed an exclusive licensing agreement with Marina Biotech for delivery and chemistry technologies.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Enzon, Zhejiang sign licensing deal for PEGylation linker technology
Enzon Pharmaceuticals has entered into a licensing collaboration with Zhejiang Hisun Pharmaceuticals for PEGylation linker technology.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Aeterna, Keryx terminate perifosine license agreement
Aeterna Zentaris and Keryx Biopharmaceuticals have announced the termination of license agreement related to perifosine, Akt inhibitor anticancer compound.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests
Contract Research & Services > Contract Services > News
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity.
Buy online from $3500